|
Press Releases |
|
|
|
Thursday, August 27, 2020 |
|
李氏大药厂公布2020中期业绩 |
结合研究主导和市场导向的中国药品制造公司 - 李氏大药厂控股有限公司 (「李氏大药厂」或「集团」;股票编号︰950),今天宣布截至2020年6月30日止(「回顾期内」)的中期业绩。 more info >> |
|
李氏大藥廠公佈2020中期業績 |
結合研究主導和市場導向的中國藥品製造公司 - 李氏大藥廠控股有限公司 (「李氏大藥廠」或「集團」;股票編號︰950),今天宣佈截至2020年6月30日止(「回顧期內」)的中期業績。 more info >> |
|
Lee's Pharm Announces 2020 Interim Results |
Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or the "Group"; HKG: 950), an integrated research-driven and market-oriented pharmaceutical group in China, today announced its interim results for the six months ended 30 June 2020 (the "period under review"). more info >> |
|
Thursday, November 28, 2019 |
|
李氏大药厂公布2019年第三季度业绩 |
结合研究主导和市场导向的中国药品制造公司- 李氏大药厂控股有限公司(「李氏大药厂」或「集团」;股票编号︰950),今天宣布截至2019年9月30日止九个月(「回顾期内」)之未经审核综合季度财务业绩。 more info >> |
|
李氏大藥廠公佈2019年第三季度業績 |
結合研究主導和市場導向的中國藥品製造公司 - 李氏大藥廠控股有限公司 (「李氏大藥廠」或「集團」;股票編號︰950),今天宣佈截至2019年9月30日止九個月(「回顧期內」)之未經審核綜合季度財務業績。 more info >> |
|
Lee's Pharm Announces 2019 Third Quarterly Results |
Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or the "Group", Stock Code: 950), an integrated research-driven and market-oriented pharmaceutical group in China, today announced its unaudited consolidated quarterly financial results for the nine months ended 30 September 2019 (the "period under review"). more info >> |
|
Thursday, October 31, 2019 |
|
COPFL宣布其全资附属公司ZKO自主研发的产品环孢霉素A眼科凝胶的II期临床研究已完满完成 |
China Ophthalmology Focus Limited(「COPFL」)今天宣布,其全资附属公司兆科(广州)眼科药物有限公司(「ZKO」) 自主研发的产品环孢霉素A眼科凝胶的II期临床研究已完满完成(clinicaltrials.gov登记号码:NCT03676335)。顶线数据显示,与市售环孢霉素A眼科乳剂相比,实验药物具有相似或更好的疗效趋势。 more info >> |
|
COPFL宣布其全資附屬公司ZKO自主研發的產品環孢霉素A眼科凝膠的II期臨床研究已完滿完成 |
China Ophthalmology Focus Limited(「COPFL」)今天宣布,其全資附屬公司兆科(廣州)眼科藥物有限公司(「ZKO」) 自主研發的產品環孢霉素A眼科凝膠的II期臨床研究已完滿完成(clinicaltrials.gov登記號碼:NCT03676335)。頂線數據顯示,與市售環孢霉素A眼科乳劑相比,實驗藥物具有相似或更好的療效趨勢。 more info >> |
|
COPFL announced that its wholly-owned subsidiary-ZKO, has successfully completed a Phase II trial of Cyclosporine A Ophthalmic Gel |
China Ophthalmology Focus Limited ("COPFL") today announced that its wholly-owned subsidiary, Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Limited ("ZKO"), has successfully completed a Phase II trial of Cyclosporine A (CsA) Ophthalmic Gel in China (clinicaltrials.gov registration No.:NCT03676335). Topline data show that the experimental drug has similar or a trend towards better efficacy than that of the marketed CsA Ophthalmic Emulsion. more info >> |
|
Thursday, March 28, 2019 |
|
李氏大药厂公布2018年全年业绩 |
结合研究主导和市场导向的中国药品制造公司-李氏大药厂控股有限公司(「李氏大药厂」或「集团」;股票编号︰950),今天宣布截至2018年12月31日止的全年业绩(「回顾年内」)。 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Finerca Celebrates Milestone of 10,000 Clients with Launch of Exclusive Master Course in CFD Trading
Mar 29, 2024 06:48: JST
|
|
|
Finerca Celebrates Milestone of 10,000 Clients with Launch of Exclusive Master Course in CFD Trading
Mar 29, 2024 05:36 HKT/SGT
|
|
|
Atlas Lithium Secures US$ 30,000,000 Strategic Investment and Offtake Agreement from Mitsui
Mar 28, 2024 19:09 HKT/SGT
|
|
|
王朝酒业公布2023年全年业绩
Mar 28, 2024 17:45 HKT/SGT
|
|
|
王朝酒業公佈2023年全年業績
Mar 28, 2024 17:42 HKT/SGT
|
|
|
Dynasty Fine Wines Announces 2023 Annual Results
Mar 28, 2024 17:35 HKT/SGT
|
|
|
东软教育:内生高质量发展 数字化赋能打开长远增长空间
Mar 28, 2024 16:45 HKT/SGT
|
|
|
東軟教育:內生高質量發展 數字化賦能打開長遠增長空間
Mar 28, 2024 16:42 HKT/SGT
|
|
|
Mitsubishi Shipbuilding Receives Order from the University of Tokyo for "MiPoLin" Power Prediction and Lines Selection System
Mar 28, 2024 16:45 JST
|
|
|
浙江沪杭甬:业绩稳健向好 积极回馈股东 分红总额增长17.7%
Mar 28, 2024 15:43 HKT/SGT
|
|
|
浙江滬杭甬:業績穩健向好 積極回饋股東 分紅總額增長17.7%
Mar 28, 2024 15:37 HKT/SGT
|
|
|
2023年收入、利潤實現「雙增長」 復星下一步:「深挖礦」,穩盈利
Mar 28, 2024 15:31 HKT/SGT
|
|
|
Fosun's Next Step: "Deep Mining" for Stable Profits
Mar 28, 2024 15:26 HKT/SGT
|
|
|
国际债券持有人特别团体(“持有人特别团体”)指示受托人 向香港上市公司希教国际控股(1765.HK)送达清盘呈请书
Mar 28, 2024 15:21 HKT/SGT
|
|
|
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 Study
Mar 28, 2024 14:42 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|